From MarketBeat:

Investment analysts at Wedbush have reissued their “outperform” rating for shares of Pacira BioSciences, and have set the company’s stock price target at $57.00. The rating implies a potential upside of 66.33% from the stock’s current closing price. Meanwhile, analysts from TheStreet lowered Pacira BioSciences’ rating from “c” to “d+” and Piper Sandler also cut their price target on the stock.

Pacira BioSciences’ stock traded at $34.27 on Friday, an increase of $1.85. The company saw 599,555 shares traded. The stock currently has a debt-to-equity ratio of 0.62, a quick ratio of 3.74, and a current ratio of 4.78. It also holds a market cap of $1.59 billion, a PE ratio of 380.78 and a beta of 0.74. Its 50-day moving average is $29.59 and its 200-day moving average is $33.20.

Pacira BioSciences reported $0.52 earnings per share (EPS) for the quarter that ended on November 2nd. This missed analysts’ consensus estimates of $0.65 by ($0.13). The company had a net margin of 1.05% and a return on equity of 12.16%. Pacira’s revenue for the quarter was $163.93 million, lower than analyst estimates of $172.83 million. Analysts anticipate the company will post 2.14 EPS for the current year.

Institutional investors, including Vanguard Group and Baillie Gifford & Co., have been buying and selling shares of Pacira BioSciences in the past year. Vanguard Group now holds 4,868,445 shares of the company’s stock, worth $258,953,000, after purchasing an additional 55,188 shares in the last quarter.

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.



Read more: Pacira BioSciences (NASDAQ:PCRX) Given Outperform Rating at Wedbush